
Annual report 2025
added 02-03-2026
Intuitive Surgical Cash Flow 2011-2026 | ISRG
Annual Cash Flow Intuitive Surgical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
3.03 B | 2.42 B | 1.81 B | 1.49 B | 2.09 B | 1.48 B | 1.6 B | 1.17 B | 1.14 B | 1.09 B | 806 M | 665 M | 880 M | 814 M | 678 M |
Depreciation & Amortization |
600 M | 439 M | 382 M | 326 M | 280 M | 221 M | 157 M | 106 M | 82.1 M | 70.7 M | 61.1 M | 52 M | 46 M | 34.7 M | 28.7 M |
Accounts Payables |
255 M | 193 M | 189 M | 147 M | 121 M | 81.6 M | 124 M | 101 M | 82.5 M | 68.5 M | 52.6 M | 61.6 M | 46.2 M | 57.6 M | 45.8 M |
Accounts Receivables |
1.53 B | 1.23 B | 1.13 B | 942 M | 783 M | 646 M | 645 M | 682 M | 512 M | 430 M | 394 M | 315 M | 301 M | 370 M | 298 M |
Total Inventories |
1.84 B | 1.49 B | 1.22 B | 893 M | 587 M | 602 M | 596 M | 409 M | 241 M | 182 M | 168 M | 182 M | 180 M | 122 M | 112 M |
All numbers in USD currency
Quarterly Cash Flow Intuitive Surgical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 582 M | - | - | - | 265 M | - | - | - | 371 M | - | 1.05 B | - | 223 M | - | 1.52 B | - | 478 M | - | 857 M | 583 M | 353 M | - | 1.05 B | 649 M | 333 M | - | 832 M | 512 M | 280 M | - | 812 M | 458 M | 242 M | - | 757 M | 488 M | 227 M | - | 488 M | 309 M | 124 M | - | 471 M | 320 M | 166 M | - | 651 M | 447 M | 258 M | - | 587 M | 376 M | 165 M | - | 464 M | 306 M | 105 M |
Depreciation & Amortization |
3.3 M | 3.2 M | 3.4 M | - | 3.5 M | 5 M | 5.1 M | - | 5.1 M | 5 M | 5 M | - | 7.9 M | - | 6.1 M | - | 6.3 M | 7.5 M | 64.8 M | - | 159 M | 102 M | 51.1 M | - | 108 M | 67.8 M | 31.6 M | - | 76.8 M | 49.8 M | 23.7 M | - | 61.4 M | 39.6 M | 19 M | - | 54 M | 36 M | 18.3 M | - | 46.3 M | 28.9 M | 14 M | - | 38.2 M | 24.8 M | 12.3 M | - | 32.6 M | 21.3 M | 10.4 M | - | 25.2 M | 15.2 M | 7.5 M | - | 20.9 M | 13.8 M | 6.9 M |
Accounts Payables |
291 M | 267 M | 276 M | 193 M | 219 M | 194 M | 194 M | 189 M | 196 M | - | 164 M | 147 M | 164 M | - | 128 M | 121 M | 120 M | 118 M | 103 M | 81.6 M | 81.6 M | 81.6 M | 81.6 M | 124 M | 124 M | 124 M | 124 M | 101 M | 101 M | 101 M | 101 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | 68.5 M | 68.5 M | 68.5 M | 68.5 M | 52.6 M | 52.6 M | 52.6 M | 52.6 M | 61.6 M | 61.6 M | 61.6 M | 61.6 M | 46.2 M | 46.2 M | 46.2 M | 46.2 M | 57.6 M | 57.6 M | 57.6 M | 57.6 M | 45.8 M | 45.8 M | 45.8 M | 45.8 M |
Accounts Receivables |
1.26 B | 1.27 B | 1.22 B | 1.23 B | 1.15 B | 1.11 B | 1.13 B | 1.13 B | 963 M | - | 925 M | 942 M | 850 M | - | 906 M | 783 M | 695 M | 700 M | 654 M | 646 M | 646 M | 646 M | 646 M | 645 M | 645 M | 645 M | 645 M | 682 M | 682 M | 682 M | 682 M | 508 M | 508 M | 508 M | 508 M | 430 M | 430 M | 430 M | 430 M | 394 M | 394 M | 394 M | 394 M | 315 M | 315 M | 315 M | 315 M | 301 M | 301 M | 301 M | 301 M | 370 M | 370 M | 370 M | 370 M | 298 M | 298 M | 298 M | 298 M |
Total Inventories |
1.78 B | 1.67 B | 1.55 B | 1.49 B | 1.48 B | 1.38 B | 1.3 B | 1.22 B | 1.15 B | - | 947 M | 893 M | 837 M | - | 653 M | 587 M | 585 M | 570 M | 577 M | 602 M | 602 M | 602 M | 602 M | 596 M | 596 M | 596 M | 596 M | 409 M | 409 M | 409 M | 409 M | 241 M | 241 M | 241 M | 241 M | 182 M | 182 M | 182 M | 182 M | 168 M | 168 M | 168 M | 168 M | 182 M | 182 M | 182 M | 182 M | 180 M | 180 M | 180 M | 180 M | 122 M | 122 M | 122 M | 122 M | 112 M | 112 M | 112 M | 112 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Intuitive Surgical, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Harvard Bioscience
HBIO
|
$ 5.16 | -3.37 % | $ 229 M | ||
|
Repro Med Systems
KRMD
|
$ 4.38 | -1.13 % | $ 202 M | ||
|
LeMaitre Vascular
LMAT
|
$ 110.38 | 2.34 % | $ 2.5 B | ||
|
Masimo Corporation
MASI
|
$ 178.36 | -0.04 % | $ 9.51 B | ||
|
Merit Medical Systems
MMSI
|
$ 67.9 | -0.34 % | $ 4.02 B | ||
|
ICU Medical
ICUI
|
$ 129.59 | -0.26 % | $ 3.19 B | ||
|
Pro-Dex
PDEX
|
$ 49.01 | 2.21 % | $ 161 M | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Envista Holdings Corporation
NVST
|
$ 26.1 | 1.08 % | $ 4.38 B | ||
|
Pulse Biosciences
PLSE
|
$ 21.4 | 2.25 % | $ 1.44 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 10.61 | 0.09 % | $ 25.7 M | ||
|
Repligen Corporation
RGEN
|
$ 116.93 | 0.5 % | $ 6.52 M | ||
|
STERIS plc
STE
|
$ 224.05 | 1.38 % | $ 22.1 B | ||
|
Stereotaxis
STXS
|
- | - | $ 160 M | ||
|
Nephros
NEPH
|
$ 3.02 | -2.84 % | $ 31.4 M | ||
|
Haemonetics Corporation
HAE
|
$ 57.32 | -1.95 % | $ 2.88 B | ||
|
Baxter International
BAX
|
$ 16.7 | 0.54 % | $ 8.57 B | ||
|
Teleflex Incorporated
TFX
|
$ 106.76 | 0.75 % | $ 4.76 B | ||
|
OraSure Technologies
OSUR
|
$ 3.13 | 1.62 % | $ 230 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
AngioDynamics
ANGO
|
$ 10.59 | -1.17 % | $ 433 M | ||
|
AtriCure
ATRC
|
$ 29.65 | -0.44 % | $ 1.42 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.57 | -0.31 % | $ 198 M | ||
|
Utah Medical Products
UTMD
|
$ 62.61 | -3.87 % | $ 227 M | ||
|
iRhythm Technologies
IRTC
|
$ 118.53 | 0.33 % | $ 3.79 B | ||
|
BioLife Solutions
BLFS
|
$ 19.81 | 3.34 % | $ 913 M | ||
|
Milestone Scientific
MLSS
|
$ 0.31 | 9.08 % | $ 24.7 M | ||
|
electroCore
ECOR
|
$ 6.17 | 0.65 % | $ 52.3 K | ||
|
The Cooper Companies
COO
|
$ 70.44 | 0.28 % | $ 14 B | ||
|
West Pharmaceutical Services
WST
|
$ 246.92 | 2.29 % | $ 17.9 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Glaukos Corporation
GKOS
|
$ 105.75 | -1.02 % | $ 5.12 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.66 | 1.0 % | $ 2.33 B | ||
|
ResMed
RMD
|
$ 229.36 | 0.61 % | $ 33.5 B | ||
|
Microbot Medical
MBOT
|
$ 2.49 | -1.39 % | $ 25.4 M | ||
|
Retractable Technologies
RVP
|
$ 0.72 | -0.39 % | $ 21.6 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
STAAR Surgical Company
STAA
|
$ 19.17 | 3.57 % | $ 950 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 155.19 | -0.67 % | $ 44.6 B | ||
|
Alcon
ALC
|
$ 74.28 | 0.19 % | $ 40.4 B |